Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.

Journal of Clinical Microbiology

Volumn 45, Issue 11, 2007, Pages 3522-3528

  Pfaller, M A ^a   Diekema, D J ^a   Procop, G W ^b,d   Rinaldi, M G ^c  

^a UNIVERSITY OF IOWA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCYTOSINE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOMATION; BROTH MICRODILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA NORVEGENSIS; CANDIDA PARAPSILOSIS; CANDIDA PELLICULOSA; CANDIDA TROPICALIS; CONTROLLED STUDY; FUNGAL STRAIN; FUNGUS ISOLATION; INCUBATION TIME; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; SPECTROPHOTOMETRY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CULTURE MEDIA; FLUCYTOSINE; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; REFERENCE STANDARDS; TIME FACTORS; TRIAZOLES;

CANDIDA;

EID: 36348937967     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00403-07     Document Type: Article

References (42)

1. Alexander B. D., and M. A. Pfaller. 2006. Contemporary tools for the diagnosis and management of invasive mycosis. Clin. Infect. Dis. 43(Suppl. 1):S15-S27.
2. Arthington-Skaggs, B. A., W. Lee-Yang, M. A. Ciblak, et al. 2002. Comparison of visual and spectrophotometric methods of broth microdilution MIC endpoint determination and evaluation of sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob. Agents Chemother. 46:2477-2481.
3. Asmundsdottir, L. R., H. Erlendsdottir, and M. Gotfredsson. 2002. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J. Clin. Microbiol. 40:3489-3492.
4. Aubertine, C. L., M. Rivera, S. M. Rohan, and D. H. Larone. 2006. Comparative study of the new colorimetric VITEK 2 yeast identification card versus the older fluorometric card and of CHROMagar Candida as a source medium with the new card. J. Clin. Microbiol. 44:227-228.
5. Barry, A. L., M. A. Pfaller, S. D. Brown, et al. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 28:3457-3459.
6. Chen, Y. C., S. C. Chang, K. T. Luh, and W. C. Hsieh. 2002. Stable susceptibility of Candida bloodstream isolates to fluconazole despite increasing use during the past 10 years. J. Antimicrob. Chemother. 52:71-77.
7. Cuenca-Estrella, M., A. Gomez-Lopez, E. Mellado, and J. L. Rodriguez-Tudela. 2005. Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques. Clin. Microbiol. Infect. 11:486-492.
8. Cuenca-Estrella, M., C. B. Moore, F. Barchiesi, et al. 2003. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin. Microbiol. Infect. 9:467-474.
9. Cuenca-Estrella, M., W. Lee-Yang, M. A. Ciblak, et al. 2002. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob. Agents Chemother. 46:3644-3647.
10. Espinel-Ingroff, A., F. Barchiesi, M. Cuenca-Estrella, et al. 2005. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. J. Clin. Microbiol. 43:4535-4540.
11. Espinel-Ingroff, A., F. Barchiesi, M. Cuenca-Estrella, et al. 2005. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibility of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J. Clin. Microbiol. 43:3884-3889.
12. Espinel-Ingroff, A., M. A. Pfaller, S. A. Messer, et al. 2004. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J. Clin. Microbiol. 42:718-721.
13. Espinel-Ingroff, A., M. A. Pfaller, S. A. Messer, et al. 1999. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeast and yeast-like organisms. J. Clin. Microbiol. 37:591-595.
14. Garey, K. W., M. Rege, M. P. Pai, et al. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
15. Hazen, K. C., and S. A. Howell. 2003. Candida, Cryptococcus, and other yeasts of medical importance, p. 1693-1711. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed. ASM Press, Washington, DC.
16. Magill, S. S., C. Shields, C. L. Sears, M. Choti, and W. G. Merz. 2006. Triazole-cross resistance among Candida spp.: case report, occurrence among blood stream isolates, and implication for antifungal therapy. J. Clin. Microbiol. 44:529-535.
17. Matar, M. J., L. Ostrosky-Zeichner, V. L. Paetznick, et al. 2003. Correlation between E-test disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob. Agents Chemother. 47:1647-1651.
18. Morace, G., G. Amato, F. Bistoni, et al. 2002. Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fluconazole susceptibility testing of Candida species. J. Clin. Microbiol. 40:2953-2958.
19. Morrell, M., V. J. Fraser, and M. J. Kollef. 2005. Delaying empirical treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for mortality. Antimicrob. Agents Chemother. 49:3640-3645.
20. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeast. M27-A. National Committee for Clinical Laboratory Standards, Villanova, PA.
21. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 2nd ed., M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
22. Nguyen M. H., and C. Y. Yu. 1999. Influence of incubation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole and itraconazole. J. Clin. Microbiol. 37:141-145.
23. Pappas, P. G., J. H. Rex, J. D. Sobel, et al. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
24. Park, B. J., B. A. Arthington-Skaggs, R. A. Hajjeh, et al. 2006. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob. Agents Chemother. 50:1287-1292.
25. Pfaller, M. A. 2005. Antifungal susceptibility testing methods. Curr. Drug Targets 6:929-943.
26. Pfaller, M. A., A. Espinel-Ingroff, and R. N. Jones. 2004. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J. Clin. Microbiol. 42:4577-4580.
27. Pfaller, M. A., D. J. Diekema, and D. J. Sheehan. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
28. Pfaller, M. A., D. J. Diekema, G. W. Procop, and M. G. Rinaldi. 2007. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J. Clin. Microbiol. 45:796-802.
29. Pfaller, M. A., D. J. Diekema, J. H. Rex, et al. 2006. Correlation of MIC with outcome for Candida species against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
30. Pfaller, M. A., K. C. Hazen, S. A. Messer, et al. 2004. Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 42:3607-3612.
31. Pfaller, M. A., L. Boyken, R. J. Hollis, et al. 2004. Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans. Diagn. Microbiol. Infect. Dis. 50:113-117.
32. Pfaller, M. A., L. Boyken, S. A. Messer, et al. 2004. Evaluation of the Etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species. J. Clin. Microbiol. 42:4977-4979.
33. Pfaller, M. A., L. Boyken, S. A. Messer, et al. 2005. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 43:5208-5213.
34. Pfaller, M. A., and R. N. Jones, for the Microbiology Resource Committee of the College of American Pathologists. 2006. Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists (CAP) Microbiology Surveys Program (2001-2003). Arch. Pathol. Lab. Med. 130:767-778.
35. Pfaller, M. A., S. A. Messer, L. Boyken, et al. 2002. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob. Agents Chemother. 46:3518-3521.
36. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and D. J. Diekema. 2002. In vitro activities of ravuconazole and voriconazole compared with those of four approved systematic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:1723-1727.
37. Rex, J. H., M. A. Pfaller, J. N. Galgiani, et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
38. Rex, J. H., M. A. Pfaller, T. J. Walsh, et al. 2001. Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. 14:643-658.
39. Rodriguez-Tudela, J. L., F. Barchiesi, J. Bille, et al. 2003. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clin. Microbiol. Infect. 9:I-VIII.
40. Rodriguez-Tudela, J. L., M. Cuenca-Estrella, T. M. Diaz-Guerra, and E. Mellado. 2001. Standardization of antifungal susceptibility variables for a semiautomated methodology. J. Clin. Microbiol. 39:2513-2517.
41. Tortorano, A. M., A. L. Rigoni, E. Biraghi, et al. 2003. The European Confederation of Medical Mycology (ECMM) survey of candidemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J. Antimicrob. Chemother. 52:679-682.
42. Zambardi, G., D. Parreno, V. Monnin, et al. 2005. Rapid antifungal susceptibility testing of medically important yeasts with the VITEK 2 system, abstr. M-1619. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.